The chief executive of dual-listed diagnostics company Pacific Edge is confident the worst-case scenario in ongoing uncertainty over the continued reimbursement of its tests in the US is “low probability” and that it would be “unprecedented” for them to lose coverage.
The company today
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
